CN104188918B - 一种硝呋莫司干混悬剂及其制备方法 - Google Patents
一种硝呋莫司干混悬剂及其制备方法 Download PDFInfo
- Publication number
- CN104188918B CN104188918B CN201410487143.XA CN201410487143A CN104188918B CN 104188918 B CN104188918 B CN 104188918B CN 201410487143 A CN201410487143 A CN 201410487143A CN 104188918 B CN104188918 B CN 104188918B
- Authority
- CN
- China
- Prior art keywords
- nifurtimox
- dry suspension
- parts
- hydroxypropyl methylcellulose
- dry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ARFHIAQFJWUCFH-IZZDOVSWSA-N Nifurtimox Chemical compound CC1CS(=O)(=O)CCN1\N=C\C1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-IZZDOVSWSA-N 0.000 title claims abstract description 62
- 229960002644 nifurtimox Drugs 0.000 title claims abstract description 62
- 239000000725 suspension Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 239000000945 filler Substances 0.000 claims abstract description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 19
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 19
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 13
- 239000000375 suspending agent Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 239000008394 flocculating agent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 5
- 239000001509 sodium citrate Substances 0.000 claims description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007779 soft material Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000006978 adaptation Effects 0.000 abstract 1
- 238000004062 sedimentation Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010029260 Neuroblastoma Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410487143.XA CN104188918B (zh) | 2014-09-22 | 2014-09-22 | 一种硝呋莫司干混悬剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410487143.XA CN104188918B (zh) | 2014-09-22 | 2014-09-22 | 一种硝呋莫司干混悬剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104188918A CN104188918A (zh) | 2014-12-10 |
CN104188918B true CN104188918B (zh) | 2015-05-27 |
Family
ID=52074400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410487143.XA Active CN104188918B (zh) | 2014-09-22 | 2014-09-22 | 一种硝呋莫司干混悬剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104188918B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101422437A (zh) * | 2008-11-14 | 2009-05-06 | 李铁军 | 一种依托泊苷干混悬剂及其制备方法 |
WO2013169925A1 (en) * | 2012-05-08 | 2013-11-14 | Metronomx | Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity |
-
2014
- 2014-09-22 CN CN201410487143.XA patent/CN104188918B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101422437A (zh) * | 2008-11-14 | 2009-05-06 | 李铁军 | 一种依托泊苷干混悬剂及其制备方法 |
WO2013169925A1 (en) * | 2012-05-08 | 2013-11-14 | Metronomx | Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity |
Non-Patent Citations (1)
Title |
---|
管晓虹.苯并咪唑和硝呋莫司对感染不同型克氏锥虫小鼠的疗效评价.《国外医学(寄生虫病分册)》.1986,237. * |
Also Published As
Publication number | Publication date |
---|---|
CN104188918A (zh) | 2014-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020063292A (ja) | ランタン化合物を含むカプセル製剤及び粉末製剤 | |
CN103585164B (zh) | 一种溶出度增加的塞来昔布固体组合物及其制备方法和应用 | |
CN105663064A (zh) | 一种甲磺酸伊马替尼胃溶型微丸片及其制备方法 | |
JPH01501934A (ja) | メチルプレドニソロン/カルボキシメチルスターチナトリウム錠剤組成物 | |
CN101103960A (zh) | 一种含有消旋卡多曲的干混悬剂及其制备方法 | |
CN102114001A (zh) | 一种含有托伐普坦的口服固体制剂 | |
CN104940152A (zh) | 一种含有琥珀酸索利那新的药物组合物 | |
CN104434829B (zh) | 一种石菖蒲挥发油口腔速崩片及其制备方法 | |
CN106038502A (zh) | 一种雷美替胺口崩片及其制备方法 | |
CN104188918B (zh) | 一种硝呋莫司干混悬剂及其制备方法 | |
CN106880611A (zh) | 一种含微粉化的托伐普坦和水溶性辅料的托伐普坦制剂 | |
CN102860986A (zh) | 一种稳定的掩味的左西替利嗪药物组合物及其制备方法 | |
CN104721202A (zh) | 一种用于防治急性高原反应的药物 | |
CN106176752A (zh) | 色瑞替尼药物组合物 | |
CN110960501B (zh) | 一种诺氟沙星胶囊及其制备方法 | |
CN105596312B (zh) | 一种磷酸二甲啡烷胶囊组合物及其制备方法 | |
EP3345626A1 (en) | Super-rapid disintegrating tablet, and method for producing same | |
CN106176622A (zh) | 一种治疗高血压的异钩藤碱缓释制剂及其制备方法 | |
CN103860486B (zh) | 一种来曲唑口腔崩解片及其制备方法 | |
CN107397735B (zh) | 一种替莫唑胺药物组合物及其制备方法和应用 | |
CN102626420B (zh) | 一种含有锶、钙和维生素d的混合制剂 | |
JP2017530143A (ja) | アルペリシブを含む医薬組成物 | |
WO2014171307A1 (ja) | 小児への投与に適した速崩壊錠とその簡便な製造方法 | |
KR102359632B1 (ko) | 알긴산 또는 이의 약제학적으로 허용 가능한 염을 포함하는 속팽윤성 과립제, 및 이를 담지한 캡슐제 | |
WO2022063119A1 (zh) | 一种羟乙磺酸哌柏西利的组合物及药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300384 in Tianjin Binhai Huayuan Industrial Park Alex Hua Tian Road No. 2 room 2012 Patentee after: Tianjin Leah Medical Technology Development Co., Ltd. Address before: 300384 in Tianjin Binhai Huayuan Industrial Park Alex Hua Tian Road No. 2 room 2012 Patentee before: Austrian Creek Leah (Tianjin) Pharmaceutical Technology Co., Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Nifurtimox dry suspension and preparation method thereof Effective date of registration: 20160203 Granted publication date: 20150527 Pledgee: Zhejiang bank Limited by Share Ltd Tianjin Hexi Branch Pledgor: Tianjin Leah Medical Technology Development Co., Ltd. Registration number: 2016120000004 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170301 Granted publication date: 20150527 Pledgee: Zhejiang bank Limited by Share Ltd Tianjin Hexi Branch Pledgor: Tianjin Leah Medical Technology Development Co., Ltd. Registration number: 2016120000004 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Nifurtimox dry suspension and preparation method thereof Effective date of registration: 20170317 Granted publication date: 20150527 Pledgee: Zhejiang bank Limited by Share Ltd Tianjin Hexi Branch Pledgor: Tianjin Leah Medical Technology Development Co., Ltd. Registration number: 2017120000016 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180320 Granted publication date: 20150527 Pledgee: Zhejiang bank Limited by Share Ltd Tianjin Hexi Branch Pledgor: Tianjin Leah Medical Technology Development Co., Ltd. Registration number: 2017120000016 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Nifurtimox dry suspension and preparation method thereof Effective date of registration: 20180509 Granted publication date: 20150527 Pledgee: Zhejiang bank Limited by Share Ltd Tianjin Hexi Branch Pledgor: Tianjin Leah Medical Technology Development Co., Ltd. Registration number: 2018120000011 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180704 Granted publication date: 20150527 Pledgee: Zhejiang bank Limited by Share Ltd Tianjin Hexi Branch Pledgor: Tianjin Leah Medical Technology Development Co., Ltd. Registration number: 2018120000011 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Nifurtimox dry suspension and preparation method thereof Effective date of registration: 20180719 Granted publication date: 20150527 Pledgee: Zhejiang bank Limited by Share Ltd Tianjin Hexi Branch Pledgor: Tianjin Leah Medical Technology Development Co., Ltd. Registration number: 2018120000028 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190731 Granted publication date: 20150527 Pledgee: Zhejiang bank Limited by Share Ltd Tianjin Hexi Branch Pledgor: Tianjin Leah Medical Technology Development Co., Ltd. Registration number: 2018120000028 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201207 Address after: 2-4-411, Jindi Plaza, No.1 Bridge, Hedong District, Tianjin Patentee after: Tianjin antiqiumo pharmaceutical technology partnership (limited partnership) Address before: 300384 in Tianjin Binhai Huayuan Industrial Park Alex Hua Tian Road No. 2 room 2012 Patentee before: TIANJIN AOXILIYA MEDICINE TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210831 Address after: 300000 2-4-1213 Jindi square, No. 1 bridge, Hedong District, Tianjin Patentee after: Best (Tianjin) Pharmaceutical Technology Co.,Ltd. Address before: 2-4-411, Jindi Plaza, No.1 Bridge, Hedong District, Tianjin Patentee before: Tianjin antiqiumo pharmaceutical technology partnership (limited partnership) |